Abstract B23: <i>FGFR3</i> mutations and their relation to FGFR3 expression and clinical outcome in a large radical cystectomy cohort: Implications for anti-FGFR3 bladder cancer treatment?

Bas van Rhijn(The Netherlands Cancer Institute), Tahlita C.M. Zuiverloon(Erasmus MC), Alexandre R. Zlotta(University of Toronto), Michael A.S. Jewett(Princess Margaret Cancer Centre), S. A. Gotz(University of Regensburg), Yanish Soorojebally(Université de Versailles Saint-Quentin-en-Yvelines), Deric van der Schoot(Amphia Ziekenhuis), Núria Malats(Spanish National Cancer Research Centre), Ellen C. Zwarthoff(Erasmus MC), Wolfgang Otto(University of Regensburg), Arndt Hartmann(Universitätsklinikum Erlangen), Mirari Marques, Theodorus van der Kwast(Erasmus MC), Francisco X. Real(Universitat Pompeu Fabra), Damien Pouessel(Institut Claudius Regaud), Markus Eckstein(Friedrich-Alexander-Universität Erlangen-Nürnberg), François Radvanyi(Centre National de la Recherche Scientifique), Peter J. Boström(University of Turku), Yves Allory(Institut Curie), Robert Stöhr(Friedrich-Alexander-Universität Erlangen-Nürnberg), Geert van Leenders, Max M. Burger(Radboud University Nijmegen), Roman Mayr(Ospedale di Bolzano), Laura S. Mertens(Oncode Institute)
Clinical Cancer Research
August 1, 2020
Cited by 0


Related Papers